THE TIBEREND Advisory Board

The Tiberend Advisory Board for Science, Business & Technology is a group of carefully selected industry veterans who have extensive experience and successful track records in the development and commercialization of life science and healthcare products, services and technologies in both public and private companies.

Specific objectives of the advisory board include the following:

  1. To provide unique industry insights to Tiberend and its clients.
  2. To serve as a sounding board and assist in the vetting and review processes for present and proposed projects for Tiberend.  
  3. To promote good public relations and a positive image on behalf of Tiberend to the research, development, commercialization, general management and other functional disciplines with the sectors that Tiberend serves.
  4. To provide educational programs and thought leaders within the communities of the business, media, financial, healthcare and life science industries.
  5. To assist and facilitate Tiberend collaboration with key business, non-profit, governmental, media leaders and institutions in both formal and informal settings.
  6. To otherwise assist Tiberend and its clients’ ability in attaining its potential for excellence in research, innovation, and product commercialization.

Their experience ranges from venture formation to Fortune 500 companies and from the domestic U.S. market to diverse international markets. Additionally, the advisory board membership includes individuals with distinguished careers in academia, not-for-profit organizations and banking.

Members of the advisory board are willing to become involved in helping Tiberend's clients achieve the best possible results in growing their science and technology-based businesses globally.

The advisory board serves to advise Tiberend on markets, business trends and opportunities, marketing and sales needs of clients, financial and operational topics and to assist when needed in the overall strategy of Tiberend. The advisory board will also advise on matters related to products, marketing, and business strategy for products, technologies and projects as it relates to Tiberend ability to serve its clients timely and with current market knowledge so that client’s businesses excel at taking advantage of opportunities.

The advisory board will also provide, when requested, additional support services and counsel to clients on a wide variety of subjects, such as product development and commercialization, operations, financing, licensing and strategic alliances, through the Tiberend group. 

Advisory Board Members:

Neil J. Campbell, M.A., M.B.A. – Chairman

Neil J. Campbell is President and CEO of SuperNova Diagnostics®, Inc, a privately held global diagnostics company with a proprietary platform for conducting diagnostics at the site of interest with point-of-care in human health and point-of-use for non-human health applications. SuperNova Diagnostics has offices in Washington, D.C., London and Hong Kong. Additionally, Mr. Campbell also serves as Executive Chairman for Mosaigen® Corporation, a global technology development corporation with offices in America, Europe and Asia, and Chairman for Child Health Research Institute, a global children's charity.

Having held several key positions at a number of multinational pharmaceutical, healthcare, investment and life science companies, Mr. Campbell has more than 20 years of industry experience. Formerly, Mr. Campbell was a General Partner for Endeavour Capital, an Asia/Pacific private equity fund in the life sciences, cleantech and information communication technologies (ICT). He was previously President & COO/CEO for EntreMed Pharmaceuticals (Nasdaq: ENMD), a clinical-stage pharmaceutical company committed to developing a selective angiogenic kinase inhibitor, for the treatment of cancer. Prior to EntreMed, Mr. Campbell served as Senior Director of Commercial Development for Celera Genomics (NASDAQ:CRA), where he built global genomic & proteomic businesses around the human genome project.

Mr. Campbell has held General & Executive Management positions at Life Technologies, Inc. (NASDAQ: LIFE), IGEN, Inc., acquired by Roche (NASDAQ:IGEN), and Abbott Laboratories (NYSE: ABT) the global diversified healthcare company.

Kevin Carroll

Kevin Carroll has more than 15 years of executive recruiting and sales experience in the pharmaceutical, biotechnology and medical device industries. Prior to joining Heritage Partners International, he was Life Science Practice Leader at Phillips DiPisa where he focused on searches for senior executives in such roles as CEO, CFO, VP of Sales, Chief Medical Officer, as well as VPs of Regulatory, Bio Medical Informatics, Medical Affairs and Clinical Development.

Prior to Phillips DiPisa, Kevin was Director of National Accounts at The Bowdoin Group, where his work included recruiting senior-level management talent for commercial, medical and clinical affairs roles, as well as developing and managing large scale hiring projects for sales and field-based medical affairs teams. Kevin started his career in the life sciences industry selling pharmaceuticals for Bristol-Myers Squibb in Boston hospitals and clinics.

Sara Jane Demy

Sara is an expert at orchestrating and designing programs that  achieve long-term strategic objectives. Since launching Demy-Colton Life Science Advisors, Sara co-founded the Biotech Showcase™, an investor conference designed to give biotechnology companies a home at a major investor conference that originally focused on biotechnology.  She also has partnered with the Center for Biotechnology to relaunch the Life Sciences Summit as the only translational science partnering meeting. 

Prior to launching Demy-Colton Life Science Advisors, Sara was Vice President, Business Development & Investor Relations and head of the New York Office for the Biotechnology Industry Organization (BIO).  In that capacity, she was responsible for building a portfolio of dynamic and cutting-edge programs designed to help biotech companies raise capital and form strategic partnerships.

Edward L. Erickson

Edward L. Erickson is a consultant to entrepreneurial companies and venture capital firms. He has extensive experience in the life science industries having served as president, CEO or a director of more than a dozen such companies, four of which successfully completed IPOs during his tenure. He has raised a total of approximately $500,000,000 in equity and debt capital in the private and public capital markets. He also has considerable experience gained earlier in his career in defense, energy, natural resources and information technology.

Mr. Erickson has substantial board experience as a director, including chairman roles, of both private and public companies.  Mr. Erickson has also served as an independent director on several public company boards, including Barrier Therapeutics, Inc. {NASDAQ:BTRX}, a pharmaceutical company in the field of dermatology, acquired by Stiefel Laboratories, Inc. in 2008.

Daniel D’Agostino

Daniel D’Agostino is the Co-Founder and a Managing Director at American MedTech Advisors, an investment bank dedicated to providing strategic advisory and capital raising services to emerging growth companies in the tech and medical technology sectors with market capitalizations between $25 million and $500 million.

Prior to founding American MedTech Advisors, Mr. D’Agostino served as Managing Director and Head of Healthcare Investment Banking at ThinkEquity Partners. From 2007-2009 he oversaw the execution of all biotech/med tech financing and M&A transactions for the company. Before ThinkEquity, Mr. D’Agostino was recruited to serve as the acting Chief Financial Officer and Chief Business Officer at Synergy Pharmaceuticals/Callisto Pharmaceuticals (OTC: SYGP). During his three year tenure, he completed approximately $30 million in PIPE financings for the company and carried out merger discussions resulting in offers to acquire the company.

Nigel Gaymond, M.A.

In January 2010, Nigel Gaymond was appointed Chief Executive of the BioIndustry Association (BIA), which is the trade association for innovative enterprises in the UK's bioscience sector. Established in 1989, its mission is to encourage and promote a thriving, financially sound sector of the UK economy, built upon developments across the biosciences.  The BIA seeks to create economic growth, increase employment opportunities and expand the skills base.

Mr. Gaymond brings a wealth of healthcare and life science experience with over 20 years experience in the corporate affairs, business development and consulting arenas of the life science industry. He is considered a global expert on economic development strategies in the life science area and has concentrated on commercial development of products and services and accessing the various routes of governmental, industry and institutional investment options within the EU, Asia and North America. biotechnology industries as well as many healthcare and life science trade groups.

Kevin Nickels

Kevin Nickels most recently served as president and CEO of Celleration, Inc., a venture backed commercial company with a novel low-frequency ultrasound wound-healing technology called MIST Therapy®. During his nine years as CEO, Mr. Nickels led the company out of dire conditions in 2001 and ultimately powered the company through multiple rounds of debt/equity financing exceeding $70M commercialized. These efforts enabled a once unproven-disruptive technology to receive FDA clearance in 2004, capture a unique CPT code in 2007 and win initial reimbursement coverage by four CMS Payers that began in 2008. Commercialization has occurred through a hybrid of independent and direct sales focusing on 20 territories and grew from $1M in 2005 to $9.8M in 2008.

Prior to Celleration, Mr. Nickels was president and CEO of Kinesis Medical, Inc., a creative firm specializing in medical branding, medical Web sites, marketing, and graphic design.

Ashleigh Palmer

Ashleigh Palmer is President of Creative BioVentures Corp., a strategic advisory firm serving the biopharma industry.  Since founding Creative BioVentures in 2002, Mr. Palmer has undertaken several challenging corporate turnaround and startups assignments, including CEO and Chairman of Restoragen, Inc.; CEO of Canfite Biopharma, Ltd.; CEO of Critical Biologics Corp.; and most recently CEO of Unigene Laboratories, Inc.

Previously, Mr. Palmer was Vice President of Business Development at Ohmeda, Inc. During his tenure, he played an instrumental role in the $1.2 billion sale of Ohmeda to a consortium including Baxter and Becton Dickinson by spinning out Ohmeda's inhaled nitric oxide assets to found INO Therapeutics, Inc. Under his leadership as founding President and CEO, INO Therapeutics commercialized the world's first selective pulmonary vasodilator, INOmax®, establishing a $240 million plus orphan drug revenue stream. In 2007, INO Therapeutics was acquired by the critical care company Ikaria for $670 million.  Earlier in his career, Mr. Palmer held positions of increasing responsibility in sales and marketing management at Reckitt and Colman PLC and Seton Healthcare Group. He received his MBA from the University of Bradford, England and his BSc joint honors in Biochemistry and Applied Molecular Biology from the University of Manchester, England.

Rick Pierce

Rick Pierce is founder of FEP Capital Advisors, which provides finance and corporate development services to biotech, medical device and technology companies.

Mr. Pierce is an accomplished biotech and pharmaceutical financial executive with more than 27 years experience in specialty pharma, biotech financial operations, healthcare and technology finance. In his last three companies, Mr. Pierce served as a senior finance officer, raised more than $335 million dollars combined and successfully closed a number of strategic business development deals, including a buyout from a NYSE-listed pharmaceutical company. In addition to his finance responsibilities, Mr. Pierce has also overseen the business development and investor relations functions of four companies, two which were pre IPO when he joined and who successfully listed on NASDAQ and NYSE Amex.

For the past 12 years he has worked with outside boards of directors comprised of senior pharmaceutical industry executives, venture capitalist and strategic investors in building start ups into successful public companies. In addition to a strong acumen for finance and accounting, he has a comprehensive understanding and broad exposure to all aspects of medical device and drug development from preclinical development, chemistry and manufacturing controls, through commercial product launch.

Prior to entering the biotech and pharmaceutical industry in 1998, Mr. Pierce spent several years on Wall Street. He has extensive capital markets and investment banking experience including, IPOs, secondary offerings, PIPEs, M&A, and sales and trading. He has been involved in US/cross border pharmaceutical and biotech business development since 1994 and involved in closing a number of successful strategic transactions. Mr. Pierce has an active network of global, senior pharmaceutical and biotech industry executives, healthcare mutual funds, hedge funds, venture capitalist, private equity funds, healthcare investment banks, equity analysts, legal and accounting relationships, including in China.

Linda M. Pullan, Ph.D.

Linda M. Pullan, Ph.D. offers biotech and pharmaceutical companies consulting in all aspects of partnering through Pullan Consulting (www.pullanconsulting.com).  Linda has a Ph.D. in Biochemistry and a B.S. in Chemistry.  Linda has more than 20 years of drug industry experience, beginning in drug discovery at Monsanto/Searle/now Pfizer and ICI/Zeneca/now AstraZeneca.

She contributed to and led teams that put AstraZeneca’s multi-billion dollar antipsychotic Seroquel® and other molecules into development.  Her business development experiences began with in-licensing technology and early drug candidates in all therapeutic areas at what is now AstraZeneca, and Dr. Pullan continued as head of oncology and hematology licensing for Amgen.  She then joined Kosan Biosciences as VP of Business Development and experienced all the tasks of out-licensing and business development in a small company.

Peter G. Savas

Peter G. Savas began his career as a senior research scientist at Bristol-Myers in Syracuse, New York. After five years at Bristol-Myers, he joined Waters Associates to pursue a career as a business leader. is impact on the performance and quality of the company’s marketing, sales and service operations led to double digit growth in revenues and profits.

In September 2000, Mr. Savas was named president and chief executive officer of Aderis Pharmaceuticals, a privately held biotech company headquartered in Hopkinton, Massachusetts. During his tenure, Mr. Savas completed a $45 million private placement at a substantial uptick in value and led the revitalization of relationships with three corporate partners, one of whom ultimately purchased the company’s primary assets at a profit to the investors, founders and employees. Mr. Savas joined (publicly traded) Alseres Pharmaceutical as its chairman and chief executive officer in September 2004.

Chris Ward

Chris Ward is a Principle of Mosaigen, Inc, a global technology development corporation. The company is headquartered in the Greater Washington D.C. area with offices and affiliate groups in Europe and Asia.

He began his career with Sanofi Pharmaceuticals, then was recruited by the world’s largest biotech company, Amgen, where as a product manager on the Nephrology Franchise, he worked on the launch of Aranesp®, a multi-billion dollar blockbuster for Amgen. As Director of Professional Affairs at Mylan Specialty Pharmaceuticals, Mr. Ward developed and launched a patient advocacy platform to support the EpiPen® product.

Mr. Ward served as Director of the Audit Resource Center for SynTegra Solutions, Inc., a pharmaceutical industry distribution audit firm where he was responsible for business development and management of the ARC database of software process audits as well as project management for the distributor audit business.

Mr. Ward has business development experience in the contract research healthcare sector and has worked in life science and technology trade associations. He has served as a volunteer Director of the Asthma and Allergy Foundation of America since 2002 in several capacities including Chair of the Board of Directors.